Hot Life Science Investor Mandate 1: US Based Family Office Seeking Medical Device, Diagnostics and HIT Investment Opportunities

~ Next Phase Admin ~ Leave a comment

A family office based in the Southern United States is currently seeking new investments in healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in the Southern U.S. but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, healthcare IT, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Japanese Pharmaceutical Company Looking for Partnering and In-Licensing Opportunities Globally

~ Next Phase Admin ~ Leave a comment

A global pharmaceutical company headquartered in Japan is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. The firm is currently looking for partnering and in-licensing opportunities across the globe.

The firm is currently looking for innovative therapeutics targeting cardiovascular-metabolic diseases including obesity, heart failure, metabolic abnormality-induced vascular dysfunction, kidney protection, and stroke. The firm also seeks new treatments for the following indications: sensory neuronal system conditions such as retinal and cochlear degeneration; pain relief through Mu-opioid receptor-dependent and non-opioid mechanisms; immune dysfunctions through mechanisms of homeostatic inflammation, APC, inflammatory factor and B cell function; and fibrosis of lung and the digestive system. However the firm is not interested in the triggers of fibrosis such as inflammation or viral infection. In addition, the firm is interested in muscle atrophy, anemia, and rare/serious diseases.

The firm is looking to partner with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Corporate VC Arm of Biopharma Company Seeking Innovative Technologies in Oncology, Immunology, and Hematology

~ Next Phase Admin ~ Leave a comment

A new corporate VC fund formed by a biopharmaceutical company is looking to invest in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is currently open to opportunities worldwide.

The firm is currently looking to invest in three indication areas: oncology, immunology, and hematology. The fund is technology-agnostic, and is therefore interested in therapeutic, medical device, diagnostic and healthcare IT opportunities in these three areas. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).

The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 4: CVC of Tech Giant Looking to Invest in Healthcare IT and Connected Devices

~ Next Phase Admin ~ Leave a comment

The corporate venture capital arm of a large tech company is currently seeking to invest the in intersection of software and biology. The fund invests in companies at a variety of developmental stages and investments therefore vary widely, but typically range from $1-10m of equity. The firm is looking for opportunities globally.

Within the medical technology sector, the firm is interested in the intersection between communication and health, and particularly in technologies that improve delivery of patient care and make care more cost-effective. Areas of focus include traditional healthcare IT (particularly data and communications in a hospital setting), personalized medicine, mobile health technology (including connected medical devices, consumer apps, and patient monitoring technologies that can be used both inside and outside hospitals), and genomic platforms that provide actionable information for patient care (technologies used purely for gene sequencing are not of interest). While it is not an area of primary focus, connected lab equipment may also be of interest.

The firm invests only in privately-held companies. The firm backs innovative, creative entrepreneurs with expertise in their fields, and who are developing solutions that will have an impact on the health marketplace.If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Breakdown of Investors You Can Meet at RESI Boston

~ Next Phase Admin ~ Leave a comment

By Michael Quigley, Director of Research, LSN

mike-2The RESI Conference was built on helping fundraising entrepreneurs connect with a diverse set of early stage healthcare investors, and with 200 anticipated investors, our next RESI in Boston this September 16th is no exception. Figure 1 below breaks down the types of investors that are currently attending the conference.

 

Figure 1 | as of August 13, 2015

While Venture Capital does represent the single largest group in attendance, the remaining 77% of investor groups belong to Family Offices, Large Pharma/Medtech, Corporate Venture Capital, Venture Philanthropy, Angel, and Private Equity Investors. As many venture capital firms have moved to later stage, more risk averse investments or have adopted a company building strategy, many of the entrepreneurs we work and interact with are getting more traction with investors outside of the traditional venture capital investor class. There are still many venture capitalists who are active in the space; however, in today’s competitive fundraising environment it is highly beneficial to target all relevant investor types, and RESI allows entrepreneurs to do just that.

Due to the work done by LSN’s dedicated investor research team, we also have visibility into the types of companies that these investors will be looking for at the event. (As many investors are interested in multiple sectors, the percentages are over 100%.)

ac2
Figure 2 | as of August 13, 2015

As can be seen above, RESI will provide an opportunity for companies across the early stage healthcare spectrum to meet with relevant investors. It is this diversity of investors attending paired with the forward-looking investor mandate information used in our partnering platform that really makes RESI stand out in terms of being able to book meaningful meetings. With partnering going live on Monday, the best time to register for the event is now before any investor meetings get booked. To see a demonstration of just how effective the partnering system can be at finding a match, please check out this video.

RESI Boston 2015 Corporate Venture Capital Announcement

~ Next Phase Admin ~ Leave a comment

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10Corporate venture capital (CVC) funds are playing an increasingly important role in the early stage ecosystem and now are participating in one out of every five VC deals in the US. Almost all major pharmaceutical companies have now established CVC funds; meanwhile giants from other industries are exploring the life sciences horizon through their CVC arms.

Moderated by Donnie Mcgrath, VP of Business Development, Bristol Myers Squibb, this panel will feature:

What technologies are on CVC managers’ dreamlist? What are their key motivators and strategies? How should entrepreneurs start a dialogue with them? Experts from five prominent CVC funds will get together on the Corporate Venture Capital panel at RESI and speak their minds on these questions. You may have read our tips on partnering with CVC funds; RESI Boston will be a unique opportunity to meet them face-to-face.

LSN Summer Reading Series Chapter 12: “Anatomy of an Allocation Process”

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, Senior Research Manager, LSN

In recent weeks we’ve covered how to make a global target list of potential investors, and the basic techniques of phone canvassing and email outreach required to initiate dialogue. This week, LSN takes a look under the hood of the investment process. How do you turn that initial spark of interest into an allocation check?

This chapter explains how you can move the process forward through the pipeline and describes the people you’ll have to work with in order to make the allocation happen—from the initial gatekeepers to the final decision-makers. We look at how to make a good first impression and how to run a productive meeting with an investor, and explore what will happen during the due diligence process. If you’re preparing to meet with a potential investor in the near future, this chapter will be invaluable.

Click here to download/print the chapter PDF

Next week, join us for Chapter 13: “Straight Talk About Finding, Vetting, and Closing Capital.”

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front